Form 4: REGENXBIO Director Stump Acquires Shares and Stock Options

Director David C. Stump acquired shares of common stock and stock options in REGENXBIO Inc. on May 31, 2024.

Summary

• On May 31, 2024, David C. Stump, a director of REGENXBIO Inc., acquired 4,790 shares of common stock through a restricted stock unit award.
• These shares were acquired at a price of $0.00.
• Following this transaction, Stump directly owns 11,286 shares of REGENXBIO Inc.
• Additionally, Stump acquired 24,454 stock options with an exercise price of $14.35, exercisable starting May 31, 2024, and expiring on May 31, 2034.
• The options vest in 12 equal monthly installments.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports insider transactions, which can be interpreted as positive or negative depending on the context and individual investor perspective.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The stock options vest in 12 equal monthly installments following May 31, 2024, subject to continuous service.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Insider transactions are routinely monitored across the biotechnology industry.
• Comparing Stump's acquisitions to those of directors at similar gene therapy companies like Sarepta Therapeutics or BioMarin Pharmaceutical could provide context on the scale and potential implications of this transaction.
• The vesting schedule and exercise price of the options are typical for executive compensation packages in the biotech sector.

Stakeholder Impact

• The transaction could influence investor sentiment, potentially affecting the stock price.

Key Dates